The patents in contention are numbers 3,109,258, 2,222,710 and 3,178,490, all awarded by the European Patent Office and covering recombinant RSV antigens and compositions and methods for making them.

Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their households, based on data from more than 3000 individuals. Previous studies ...

On average over four seasons, the study found that RSV caused 84.7 hospitalizations per 100,000 among people older than 60 years, and varied significantly depending on age and certain risk factors.

The inventors have created a reverse genetics system for RSV strain B1 of antigenic subgroup B encoding a replication-competent recombinant RSV that contains a codon-optimized G ORF and expresses ...

More Alberta seniors are now eligible for a provincially funded RSV vaccine. The provincial government announced in October it would provide the RSV shot, Abrysvo, for free to seniors 60 and up ...